Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.40 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.40 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.38 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.36 |
| ▸ | HMGCR | P04035 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 4/20 | 0.36 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2945016 | 0.86 | BLM (0.34) | LMNAEGLN1ALKBH5SUCNR1ALDH1A1 | |
| SCHEMBL2942860 | 0.86 | BLM (0.34) | LMNAEGLN1ALKBH5SUCNR1ALDH1A1 | |
| SCHEMBL2943577 | 0.86 | BLM (0.34) | LMNAEGLN1ALKBH5SUCNR1ALDH1A1 | |
| SCHEMBL2311055 | 0.85 | ALDH1A1 (0.46) | LMNAALDH1A1SLC22A6TSHRNFKB1 | |
| SCHEMBL19203186 | 0.84 | ALDH1A1 (0.33) | LMNAEGLN1ALKBH5SUCNR1ALDH1A1 | |
| SCHEMBL2398354 | 0.83 | ALDH1A1 (0.56) | LMNAALDH1A1SLC22A6TSHRNFKB1 | |
| SCHEMBL16144184 | 0.82 | HMGCR (0.40) | LMNAEGLN1ALKBH5SUCNR1ALDH1A1 | |
| SCHEMBL21510518 | 0.80 | ALDH1A1 (0.37) | LMNAEGLN1ALKBH5SUCNR1ALDH1A1 | |
| SCHEMBL18191548 | 0.80 | NAALAD2 (0.38) | LMNAEGLN1ALKBH5SUCNR1ALDH1A1 | |
| SCHEMBL8383006 | 0.79 | ALDH1A1 (0.45) | LMNAALDH1A1FFAR3SLC15A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383637-B2 | 2-amino-quinazoline derivatives useful as inhibitors of β-secretase (BACE) | JANSSSEN PHARMACEUTICA N.V. (BE) | 2013-02-26 | — | — | US | claimed |
| EP-1776349-B1 | 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-06 | — | — | EP | claimed |
| EP-1776349-A2 | 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-25 | — | — | EP | claimed |
| US-20060079687-A1 | Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-04-13 | — | — | US | claimed |
| WO-2006017836-A2 | 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-02-16 | — | — | WO | claimed |
| WO-2025098391-A9 | SELECTIVE DRUG RELEASE FROM CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | NONA BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2026-04-30 | — | — | WO | disclosed |
| WO-2025098391-A1 | SELECTIVE DRUG RELEASE FROM CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS | NONA BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2025-05-15 | — | — | WO | disclosed |
| US-11814364-B2 | Pyridine N-oxide derivatives useful as factor XIa inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-14 | — | — | US | disclosed |
| CN-114586950-B | Microwave direct heating-wave absorbing heat transfer processing method for improving pork aroma by increasing temperature | 江南大学 | 2023-09-12 | — | — | CN | disclosed |
| US-20230091768-A1 | PYRIDINE N-OXIDE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2023-03-23 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| CN-112043835-B | Bioreversible introducing group for nitrogen and hydroxyl-containing drugs | 韩捷 | 2022-10-21 | — | — | CN | disclosed |
| US-20050215605-A1 | Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor | MERCK SERONO SA (CH) | 2005-09-29 | — | — | US | disclosed |
| WO-2005007647-A9 | TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070562-A1 | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. | 2005-03-31 | — | — | US | disclosed |
| WO-2005007647-A1 | TRISUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| EP-1487442-A1 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | Applied Research Systems ARS Holding N.V. (AN) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003082278-A1 | THIAZOLIDINE CARBOXAMIDE DERIVATIVES AS MODULATORS OF THE PROSTAGLANDIN F RECEPTOR | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2003-10-09 | — | — | WO | disclosed |
| CN-1299344-A | Novel urea derivatives | SANTEN PHARCEUMATICAL CO LTD (JP) | 2001-06-13 | — | — | CN | disclosed |
| US-4725620-A | 2H-pyran-2,6-(3H)-dione derivatives with anti-allergic activity | ALLERGAN, INC. (US) | 1988-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079687-A1 | Novel 2-amino-quinazoline derivatives useful as inhibitors of beta-secretase (BACE) | BACE2, BACE1, APP | LMNA 2653/4885EGLN1 3589/4885ALKBH5 4297/4885 |
| US-20230091768-A1 | PYRIDINE N-OXIDE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS | F11, F2, KLKB1 | LMNA 1285/4885EGLN1 472/4885ALKBH5 4505/4885 |
| US-20050070562-A1 | Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto | CYP7A1, CYP27A1, SULT2A1 | LMNA 4297/4885EGLN1 741/4885ALKBH5 1833/4885 |
| US-11814364-B2 | Pyridine N-oxide derivatives useful as factor XIa inhibitors | F11, F2, KLKB1 | LMNA 1285/4885EGLN1 472/4885ALKBH5 4505/4885 |
| US-20050215605-A1 | Thiazolidine carboxamide derivatives as modulators of the prostaglandin f receptor | TBXA2R, CNR2, PTGDR | LMNA 1563/4885EGLN1 1442/4885ALKBH5 3234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.